After Years Of Development, AcelRx's Dsuvia Has Finally Generated Revenue
On Wednesday, May 8, AcelRx reported its financial results for Q1 2019 and gave updates on the Dsuvia commercialization process.
AcelRx recorded approximately $50K in revenue related to Dsuvia, and ended the quarter with around $90.2M in cash and short-term investments.Dsuvia\'s revenue figures represent sales from just 5 weeks of availability to wholesalers - as formulary approvals continue to roll in, revenue will likely increase significantly.All in all, AcelRx appears to be continuing smoothly along the planned commercialization track it has outlined in previous business updates, earnings calls, and press releases.